These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24900235)

  • 21. Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent.
    Ma D; Yu S; Li B; Chen L; Chen R; Yu K; Zhang L; Chen Z; Zhong D; Gong Z; Wang R; Jiang H; Pei G
    ChemMedChem; 2007 Feb; 2(2):187-93. PubMed ID: 17163560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CXCR4 in HIV cell-entry inhibition.
    Steen A; Schwartz TW; Rosenkilde MM
    Mini Rev Med Chem; 2009 Dec; 9(14):1605-21. PubMed ID: 20088780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
    Shiraishi M; Aramaki Y; Seto M; Imoto H; Nishikawa Y; Kanzaki N; Okamoto M; Sawada H; Nishimura O; Baba M; Fujino M
    J Med Chem; 2000 May; 43(10):2049-63. PubMed ID: 10821717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines.
    Colin P; Bénureau Y; Staropoli I; Wang Y; Gonzalez N; Alcami J; Hartley O; Brelot A; Arenzana-Seisdedos F; Lagane B
    Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9475-80. PubMed ID: 23696662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.
    Latinovic O; Schneider K; Szmacinski H; Lakowicz JR; Heredia A; Redfield RR
    Antiviral Res; 2014 Dec; 112():80-90. PubMed ID: 25453341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5.
    Carter PH; Brown GD; Cherney RJ; Batt DG; Chen J; Clark CM; Cvijic ME; Duncia JV; Ko SS; Mandlekar S; Mo R; Nelson DJ; Pang J; Rose AV; Santella JB; Tebben AJ; Traeger SC; Xu S; Zhao Q; Barrish JC
    ACS Med Chem Lett; 2015 Apr; 6(4):439-44. PubMed ID: 25893046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical discovery and development of maraviroc for the treatment of HIV.
    Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
    Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
    Imamura S; Nishikawa Y; Ichikawa T; Hattori T; Matsushita Y; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
    Bioorg Med Chem; 2005 Jan; 13(2):397-416. PubMed ID: 15598561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.
    Baba M; Miyake H; Wang X; Okamoto M; Takashima K
    Antimicrob Agents Chemother; 2007 Feb; 51(2):707-15. PubMed ID: 17116673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety.
    Seto M; Aramaki Y; Okawa T; Miyamoto N; Aikawa K; Kanzaki N; Niwa S; Iizawa Y; Baba M; Shiraishi M
    Chem Pharm Bull (Tokyo); 2004 May; 52(5):577-90. PubMed ID: 15133211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
    Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
    J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.
    Hale JJ; Budhu RJ; Holson EB; Finke PE; Oates B; Mills SG; MacCoss M; Gould SL; DeMartino JA; Springer MS; Siciliano S; Malkowitz L; Schleif WA; Hazuda D; Miller M; Kessler J; Danzeisen R; Holmes K; Lineberger J; Carella A; Carver G; Emini E
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2741-5. PubMed ID: 11591514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
    Imamura S; Ichikawa T; Nishikawa Y; Kanzaki N; Takashima K; Niwa S; Iizawa Y; Baba M; Sugihara Y
    J Med Chem; 2006 May; 49(9):2784-93. PubMed ID: 16640339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
    Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
    Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.
    Klibanov OM
    Curr Opin Investig Drugs; 2009 Aug; 10(8):845-59. PubMed ID: 19649929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.
    Zheng C; Cao G; Xia M; Feng H; Glenn J; Anand R; Zhang K; Huang T; Wang A; Kong L; Li M; Galya L; Hughes RO; Devraj R; Morton PA; Rogier DJ; Covington M; Baribaud F; Shin N; Scherle P; Diamond S; Yeleswaram S; Vaddi K; Newton R; Hollis G; Friedman S; Metcalf B; Xue CB
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1442-6. PubMed ID: 21295478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.
    Cumming JG; Tucker H; Oldfield J; Fielding C; Highton A; Faull A; Wild M; Brown D; Wells S; Shaw J
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1655-9. PubMed ID: 22266038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.